No benefit of iron chelation in haemorrhagic stroke

Trials for treatments for intracerebral bleeds may need to be extended to six months

The use of the iron chelator, deferoxamine mesylate, in patients with intracerebral haemorrhage is unlikely to bring benefit by 90 days, but six-month trials may show it has a positive impact on recovery, a US study suggests.